2024 SCI Investor Symposium – Event Playback
Presentations and discussion panels from the 2024 SCI Investor Symposium are listed chronologically below.
Opening Remarks by Brian M. Culley
2024 SCI Investor Symposium Chair, Brian M. Culley, provides an introduction to day 1 of the 2nd Annual SCI Investor Symposium on June 26, 2024.
Presenter’s Address by Marco Baptista, PhD
Chief Scientific Officer Marco Baptista, PhD, provides an introduction to the Christopher and Dana Reeve Foundation on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
Patient Focused Drug Development (PFDD) #1 – A New Collaborative Initiative
2024 SCI Investor Symposium Chair, Brian M. Culley, provides an introduction to PFDD.
Patient Focused Drug Development (PFDD) #2 – An Overview
Jonathan Stokes, MBA from AbbVie provides an overview of the PFDD program.
Patient Focused Drug Development (PFDD) #3 – A Physician’s Perspective
Steven Kirshblum, MD from the Kessler Foundation provides a physician’s perspective on collaborative efforts in spinal cord injury.
Patient Focused Drug Development (PFDD) #4 – How to Begin the Process in SCI?
Linda Jones, PT, PhD, from SCOPE & Barry Munro, BA, LLB, from the Canadian Spinal Research Organization discuss details about the process of initiating the PFDD process in spinal cord injury.
Patient Focused Drug Development (PFDD) #5 – PFDD Discussion Summary
2024 SCI Investor Symposium Chair, Brian M. Culley, provides a summary of the morning’s PFDD discussion.
Preclinical Company Session Introduction – 2024 SCI Investor Symposium
Jack Allen, CFA of Baird & Co. and Adrien Cohen of SCI Ventures provide an introduction to the preclinical company presentation session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
Inteligex – Preclinical Company Session – 2024 SCI Investor Symposium
Paul S. Bradshaw, MBA, PhD, CEO of Inteligex takes part in the preclinical company presentations session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
NeuroHagana Ltd. – Preclinical Company Session – 2024 SCI Investor Symposium
Angela Ruban, PhD, Founder & CEO of NeuroHagana Ltd., takes part in the preclinical company presentations session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
Novoron Bioscience – Preclinical Company Session – 2024 SCI Investor Symposium
Tom Gawriluk, PhD, Program Lead in Spinal Cord Injury at Novoron Bioscience, takes part in the preclinical company presentations session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
Sania Therapeutics – Preclinical Company Session – 2024 SCI Investor Symposium
Andrew J. Murray, PhD, CEO & Co-Founder of Sania Therapeutics, takes part in the preclinical company presentations session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
ReWire Medical – Preclinical Company Session – 2024 SCI Investor Symposium
Robert L. Rennaker II, PhD, Founder of ReWire Medical, takes part in the preclinical company presentations session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.
Axonis Therapeutics – Preclinical Company Session – 2024 SCI Investor Symposium
Joanna Stanicka, PhD, CEO of Axonis Therapeutics, takes part in the preclinical company presentations session on day 1 of the 2nd Annual SCI Investor Symposium – June 26, 2024.4.
Patient Focused Drug Development (PFDD) #6 – PFDD Community Working Group & Call to Action
Marco Baptista, PhD of the Christopher & Dana Reeve Foundation & 2024 SCI Investor Symposium Chair, Brian M. Culley provide an update from the PFDD working group and a call to action for cooperative efforts moving forward in SCI.
CIRM Presentation – Lila R. Collins, PhD – 2024 SCI Investor Symposium
Lila R. Collins, PhD, Associate Director, Portfolio Development & Review at the California Institute for Regenerative Medicine (CIRM), presents on Day 2 of the 2024 SCI Investor Symposium – June 27, 2024
Discussion Panel: Persons with Lived Experience – 2024 SCI Investor Symposium
Joseph Pantginis, PhD, Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., LLC moderates a panel discussion on living with SCI featuring Jerod & Hanna Nieder and Michaela & Kyle Devins – June 27, 2024
Acute Phase of SCI: A Surgeon’s Perspective by Richard G. Fessler, MD, PhD
Richard G. Fessler, MD, PhD, Professor, Department of Neurosurgery at RUSH University Medical Center provides a surgeon’s perspective on the acute phase of spinal cord injury (SCI) on day 2 of the 2nd Annual SCI Investor Symposium – June 27, 2024
SCI Trials: Successes, Failures, Demographic Considerations & Obstacles – James Guest, MD, PhD, FACS
James Guest, MD, PhD, FACS, Clinical Professor, Department of Neurological Surgery, The Miami Project to Cure Paralysis and Professor, University of Miami Miller School of Medicine provides an overview of the successes, failures, demographic considerations & obstacles in spinal cord injury (SCI) clinical trials on day 2 of the 2nd Annual SCI Investor Symposium – June 27, 2024
Complexity of Clinical Trials During Acute Rehabilitation – Steven Kirshblum, MD
Steven Kirshblum, MD, Chief Medical Officer, Kessler Foundation speaks on the complexity of spinal cord injury (SCI) clinical trials during acute rehabilitation on day 2 of the 2nd Annual SCI Investor Symposium – June 27, 2024
Subliminal Interference With Recovery After Spinal Cord Injury – Jeffrey C. Petruska, PhD
Jeffrey C. Petruska, PhD, Associate Professor, University of Louisville, Department of Anatomical Sciences and Neurobiology, KY Spinal Cord Injury Research Center, Department of Neurological Surgery speaks on subliminal interference with recovery after spinal cord injury (SCI) on day 2 of the 2nd Annual SCI Investor Symposium – June 27, 2024
2nd Annual SCI Investor Symposium Thought Leader Panel and Q&A Session
2nd Annual SCI Investor Symposium thought leader panel featuring:
– Richard Fessler, MD, PhD
– James Guest, MD, PhD, FACS
– Steven Kirshblum, MD
– Jeffrey C. Petruska, PhD
Moderated by Joseph Pantginis, PhD, Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., LLC
June 27, 2024
ONWARD Medical N.V. – Clinical Company Session – 2024 SCI Investor Symposium
Presented by Aditi Roy, Vice President, Communications at ONWARD Medical N.V. and Candy Tefertiller, PT, DPT, PhD, NCS, Executive Director of Research and Evaluation at Craig Hospital.
AbbVie – Clinical Company Session – 2024 SCI Investor Symposium
Presented by Kimberly Pfleeger, PhD, Senior Scientific Director, Neuroscience Development at AbbVie
Lineage Cell Therapeutics, Inc. – Clinical Company Session – 2024 SCI Investor Symposium
Presented by Brian M. Culley, Chief Executive Officer at Lineage Cell Therapeutics, Inc.
NervGen Pharma Corp. – Clinical Company Session – 2024 SCI Investor Symposium
Presentation by Michael Kelly, MBA, Chief Executive Officer at NervGen Pharma Corp.
Kringle Pharma – Clinical Company Session – 2024 SCI Investor Symposium
Presented by Kiichi Adachi, PhD, President and CEO of Kringle Pharma.
Questions & Answers Panel – Clinical Company Session – 2024 SCI Investor Symposium
2nd Annual SCI Investor Symposium clinical company Q&A session moderated by Joseph Pantginis, PhD, Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., LLC
June 27, 2024.
Featuring the following clinical company presenters:
Aditi Roy, VP Communications at ONWARD Medical N.V.
Kimberly Pfleeger, PhD, Sr. Scientific Director, Neuroscience Development at AbbVie Inc.
Brian Culley, CEO at Lineage Cell Therapeutics, Inc.
Michael Kelly, MBA, CEO at NervGen Pharma Corp
Kiichi Adachi, PhD, President and CEO at Kringle Pharma